CN117771344A - 西曲瑞克的应用 - Google Patents
西曲瑞克的应用 Download PDFInfo
- Publication number
- CN117771344A CN117771344A CN202311579285.4A CN202311579285A CN117771344A CN 117771344 A CN117771344 A CN 117771344A CN 202311579285 A CN202311579285 A CN 202311579285A CN 117771344 A CN117771344 A CN 117771344A
- Authority
- CN
- China
- Prior art keywords
- cetrorelix
- medicament
- acid
- group
- mcao
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700008462 cetrorelix Proteins 0.000 title claims abstract description 72
- 229960003230 cetrorelix Drugs 0.000 title claims abstract description 68
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 title claims abstract 4
- 102100035286 N-acetyl-D-glucosamine kinase Human genes 0.000 claims abstract description 65
- 210000005013 brain tissue Anatomy 0.000 claims abstract description 46
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 35
- 108010032040 N-acetylglucosamine kinase Proteins 0.000 claims abstract description 31
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 27
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 25
- 239000000556 agonist Substances 0.000 claims abstract description 20
- 230000008499 blood brain barrier function Effects 0.000 claims abstract description 18
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 16
- 206010063837 Reperfusion injury Diseases 0.000 claims abstract description 14
- 230000004064 dysfunction Effects 0.000 claims abstract description 10
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 56
- 230000014509 gene expression Effects 0.000 claims description 38
- 208000006011 Stroke Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000009251 neurologic dysfunction Effects 0.000 claims description 4
- 208000015015 neurological dysfunction Diseases 0.000 claims description 4
- 102000002029 Claudin Human genes 0.000 claims description 3
- 108050009302 Claudin Proteins 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 230000000451 tissue damage Effects 0.000 claims description 2
- 231100000827 tissue damage Toxicity 0.000 claims description 2
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 31
- 230000010410 reperfusion Effects 0.000 abstract description 23
- 230000001575 pathological effect Effects 0.000 abstract description 12
- 230000006378 damage Effects 0.000 abstract description 11
- 210000005036 nerve Anatomy 0.000 abstract description 5
- KFEFLCOCAHJBEA-ANRVCLKPSA-N cetrorelix acetate Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KFEFLCOCAHJBEA-ANRVCLKPSA-N 0.000 description 68
- 101001024511 Homo sapiens N-acetyl-D-glucosamine kinase Proteins 0.000 description 35
- 229940079593 drug Drugs 0.000 description 30
- 238000010172 mouse model Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000000302 ischemic effect Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 description 7
- 210000000269 carotid artery external Anatomy 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 229960003699 evans blue Drugs 0.000 description 7
- -1 inorganic acid salts Chemical class 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 6
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 102000003940 Occludin Human genes 0.000 description 5
- 108090000304 Occludin Proteins 0.000 description 5
- 210000004004 carotid artery internal Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 238000003032 molecular docking Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 229960001865 cetrorelix acetate Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102000000591 Tight Junction Proteins Human genes 0.000 description 2
- 108010002321 Tight Junction Proteins Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000008497 endothelial barrier function Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091006091 regulatory enzymes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LNOBZXNCABUBKK-UHFFFAOYSA-N 2,3,5-triphenyltetrazolium Chemical compound C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 LNOBZXNCABUBKK-UHFFFAOYSA-N 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 101150043097 nagK gene Proteins 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 108010027843 zonulin Proteins 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种西曲瑞克的新应用,西曲瑞克能够靶向N‑乙酰葡萄糖胺激酶并提高N‑乙酰葡萄糖胺激酶的活性,还能够降低脑缺血再灌注诱导的小鼠脑梗死体积,缓解神经功能障碍,减轻脑组织病理损伤,同时改善血脑屏障功能紊乱,作为N‑乙酰葡萄糖胺激酶激动药物在预防或/和治疗脑缺血再灌注损伤的药物中具有良好应用前景。
Description
技术领域
本发明涉及一种西曲瑞克的应用,尤其涉及一种西曲瑞克作为N-乙酰葡萄糖胺激酶激动剂药物的应用。
背景技术
脑卒中(Stroke)是严重危害人类健康和生命安全的常见难治性疾病,根据发病特征主要分为缺血性脑卒中和出血性脑卒中,其中缺血性脑卒中是最常见的卒中类型,具有高发病率、高复发率、高致死率和高致残率等特点。目前,临床所用的治疗药物如阿替普酶的治疗时间窗狭窄(至多4.5h),存在引起脑出血的潜在风险。缺血性脑卒中病理机制复杂,脑缺血再灌注(Cerebral ischemia-reperfusion injury,CIRI)发生过程中涉及诸多病理环节,主要包括氧化应激反应、炎症反应、血脑屏障破坏、兴奋性氨毒性、钙超载以及细胞凋亡等,各个环节之间相互作用、相互影响。其中血脑屏障(Blood-brain barrier,BBB)的破坏是脑缺血再灌注损伤早期的重要病理特征,其会使细胞旁通透性增加,脑水肿严重,进一步加剧神经功能损伤。因此,基于BBB早期通透性变化病理过程,寻找保护内皮屏障的潜在靶点和药物可为脑缺血再灌注损伤的防治提供新策略。
在脑卒中的发病过程中,相关代谢物及其调控酶发挥着不可替代的作用,N-乙酰葡萄糖胺(N-acetlyglucosamine,GlcNAc)代谢物在大脑中动脉闭塞再灌注(Middlecerebral artery occlusion/reperfusion,MCAO/R)模型小鼠和临床脑中风患者血清中显著升高,并确证GlcNAc可促进缺糖缺氧再复灌诱导的脑微血管内皮细胞焦亡。N-乙酰葡萄糖胺激酶(N-acetylglucosamine kinase,NAGK)是代谢物GlcNAc的关键调控酶,在哺乳动物中普遍存在,在几乎所有的组织中都检测到了NAGK mRNA和酶活性。研究表明,NAGK能够调节细胞分裂,影响神经元发育,且与动力蛋白轻链(DYNLRB1)相互作用有效抑制小鼠脑细胞中亨廷顿蛋白和α-突触核蛋白聚集,抑制ROS的产生,维持线粒体的正常形态,缓解神经退行性疾病。研究发现,NAGK在MCAO/R模型小鼠中的表达显著下降,采用腺相关病毒脑原位过表达NAGK,可降低MCAO/R诱导的小鼠脑组织中GlcNAc含量以及LDH的释放,从而改善脑组织病理损伤,发挥显著的脑保护作用,提示靶向NAGK的激动剂是治疗脑缺血再灌注损伤的潜在药物,然而目前缺乏该类激动剂的发现和报道。
虽然目前全球在缺血性脑卒中的病理机制和诊断方面已经取得了很大的进步,但仍缺乏特效治疗药物。目前治疗急性缺血性脑卒中的手段主要为t-PA溶栓治疗,但它会引起再灌注损伤,进一步加重脑损伤,相关治疗药物仍处于非常紧缺的状态。而血脑屏障是脑缺血再灌注发生后关键的病理始动环节。故基于血脑屏障早期通透性变化病理过程,寻找保护内皮屏障的药物可为脑缺血再灌注损伤的防治提供新策略,具有广阔的市场空间。
发明内容
发明目的:本发明旨在提供一种西曲瑞克作为N-乙酰葡萄糖胺激酶激动剂药物的应用。
技术方案:本发明所述的西曲瑞克应用于制备预防或/和治疗脑血管疾病、神经退行性疾病的药物中。
优选,所述药物为预防或/和治疗脑卒中的药物。
进一步优选,所述药物为预防或/和治疗缺血性脑卒中的药物。
更进一步优选,所述药物为预防或/和治疗脑缺血再灌注损伤的药物。
再进一步优选,所述药物能够减少脑梗死体积,缓解神经功能障碍,改善脑组织损伤;能够上调脑组织中紧密连接蛋白(ZO-1、Occludin)的表达水平;能够下调金属基质蛋白酶(MMP-9和MMP-2)的表达水平。
优选,所述药物为N-乙酰葡萄糖胺激酶激动剂药物。
进一步优选,所述药物能够提高N-乙酰葡萄糖胺激酶活性或/和表达水平,改善血脑屏障功能紊乱。
本发明通过检索DrugBank药物数据库,筛选发现得分最高的上市药物西曲瑞克(Cetrorelix acetate,CTX),通过分子对接技术发现西曲瑞克与N-乙酰葡萄糖胺激酶之间具有较好的结合能,并采用N-乙酰葡萄糖胺激酶试剂盒检测西曲瑞克对N-乙酰葡萄糖胺激酶的激动作用,最后采用MST技术验证了西曲瑞克能够与N-乙酰葡萄糖胺激酶相结合。在体内采用MCAO/R模型小鼠,发现西曲瑞克能够通过提高N-乙酰葡萄糖胺激酶活性及表达水平,改善血脑屏障功能紊乱,从而减轻脑缺血再灌注损伤。本发明为NAGK的靶向激动剂西曲瑞克的发现及该激动剂在制备治疗脑缺血性再灌注损伤药物中的应用提供了重要参考依据和数据支撑。
本发明所述的西曲瑞克的药学上可接受的盐也能够应用于上述场景,药学上可接受的盐为西曲瑞克与选自如下任一的酸形成的盐:
盐酸、氢溴酸、硫酸、磷酸、碳酸、甲磺酸、苯磺酸、对甲苯磺酸、萘磺酸、柠檬酸、苹果酸、酒石酸、乳酸、丙酮酸、乙酸、马来酸、琥珀酸、富马酸、水杨酸、苯基乙酸、杏仁酸、阿魏酸。
“药学上可接受的盐”是指化合物的盐,由具有特定取代基的化合物与相对无毒的酸或碱制备。当化合物中含有相对酸性的官能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物的游离体形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括钠、钾、钙、铵、有机氨或镁盐或类似的盐。当化合物中含有相对碱性的官能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物的游离体形式接触的方式获得酸加成盐。药学上可接受的酸加成盐的实例包括无机酸盐,所述无机酸包括例如盐酸、氢溴酸、硝酸、碳酸(形成碳酸盐或碳酸氢盐)、磷酸(形成磷酸盐、磷酸一氢盐、磷酸二氢盐、硫酸(形成硫酸盐或硫酸氢盐)、氢碘酸、亚磷酸等;以及有机酸盐,所述有机酸包括如乙酸、丙酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸、酒石酸和甲磺酸等类似的酸;有机酸盐还包括氨基酸(如精氨酸等)、葡糖醛酸等有机酸的盐。当某些特定的化合物含有碱性和酸性的官能团,从而可以被转换成任一碱或酸加成盐。优选地,以常规方式使盐与碱或酸接触,再分离母体化合物,由此再生化合物的游离体形式。化合物的游离体形式与其各种盐的形式的不同之处在于某些物理性质,例如在极性溶剂中的溶解度不同。
“药学上可接受的盐”可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下,这样的盐的制备方法是:在水或有机溶剂或两者的混合物中,经由游离酸或碱形式的这些化合物与化学计量的适当的碱或酸反应来制备。一般地,优选醚、乙酸乙酯、乙醇、异丙醇或乙腈等非水介质。
本发明所述的以西曲瑞克作为活性成分的药物组合应用于制备预防或/和治疗脑缺血再灌注损伤的药物中。
所述药物组合物中还含有药学上可接受的载体。
“药学上可接受的载体”可为药物生产领域中广泛采用的辅料。辅料主要用于提供一个安全、稳定和功能性的药物组合物,还可以提供方法,使受试者接受给药后活性成分以所期望的速率溶出,或促进受试者接受组合物给药后活性成分得到有效吸收。所述的药用辅料可以是惰性填充剂,或者提供某种功能,例如稳定该组合物的整体pH值或防止组合物活性成分的降解。所述的药用辅料可以包括下列辅料中的一种或多种:粘合剂、助悬剂、乳化剂、稀释剂、填充剂、成粒剂、胶粘剂、崩解剂、润滑剂、抗粘着剂、助流剂、润湿剂、胶凝剂、吸收延迟剂、溶解抑制剂、增强剂、吸附剂、缓冲剂、螯合剂、防腐剂、着色剂、矫味剂和甜味剂。
本发明所述的药物组合物可根据公开的内容使用本领域技术人员已知的任何方法来制备。例如,常规混合、溶解、造粒、乳化、磨细、包封、包埋或冻干工艺。
本发明所述的药物组合物可以任何形式给药,包括注射(静脉内)、粘膜、口服(固体和液体制剂)、吸入、眼部、直肠、局部或胃肠外(输注、注射、植入、皮下、静脉内、动脉内、肌内)给药。本发明的药物组合物还可以是控释或缓释剂型(例如脂质体或微球)。固体口服制剂的实例包括但不限于粉末、胶囊、囊片、软胶囊剂和片剂。口服或粘膜给药的液体制剂实例包括但不限于悬浮液、乳液、酏剂和溶液。局部用制剂的实例包括但不限于乳剂、凝胶剂、软膏剂、乳膏剂、贴剂、糊剂、泡沫剂、洗剂、滴剂或血清制剂。胃肠外给药的制剂实例包括但不限于注射用溶液、可以溶解或悬浮在药学上可接受载体中的干粉制剂、注射用悬浮液和注射用乳剂。所述的药物组合物的其它合适制剂的实例包括但不限于滴眼液和其他眼科制剂;气雾剂,如鼻腔喷雾剂或吸入剂;适于胃肠外给药的液体剂型;栓剂以及锭剂。
有益效果:与现有技术相比,本发明具有如下显著优点:
西曲瑞克能够靶向N-乙酰葡萄糖胺激酶并提高N-乙酰葡萄糖胺激酶的活性,还能够降低脑缺血再灌注诱导的小鼠脑梗死体积,缓解神经功能障碍,减轻脑组织病理损伤,同时改善血脑屏障功能紊乱,作为N-乙酰葡萄糖胺激酶激动药物在预防或/和治疗脑缺血再灌注损伤的药物中具有良好应用前景。
附图说明
图1为西曲瑞克与NAGK的对接结果;
图2为体外检测西曲瑞克对N-乙酰葡萄糖胺激酶活性的激动作用结果;
图3为MST检测西曲瑞克与N-乙酰葡萄糖胺激酶的相互作用结果;
图4为西曲瑞克减小MCAO/R模型小鼠的脑梗死体积的结果(mean±SD,n=6,##P<0.01vs.Sham group,**P<0.01vs.Model group);
图5为西曲瑞克改善MCAO/R模型小鼠脑组织病理损伤以及神经功能损伤的结果(mean±SD,n=3-6,##P<0.01vs.Sham group,**P<0.01vs.Model group);
图6为西曲瑞克减少MCAO/R模型小鼠脑组织中伊文思蓝的渗漏量的结果(mean±SD,n=6,##P<0.01vs.Sham group,**P<0.01vs.Model group);
图7为西曲瑞克增加MCAO/R模型小鼠脑组织中紧密连接蛋白的表达(mean±SD,n=3,##P<0.01vs.Sham group,**P<0.01vs.Model group);
图8为西曲瑞克降低MCAO/R模型小鼠脑组织中金属基质蛋白酶MMP-2/9的表达结果(mean±SD,n=3,##P<0.01vs.Sham group,**P<0.01vs.Model group);
图9为激动剂西曲瑞克对MCAO/R模型小鼠脑组织中NAGK蛋白水平和基因水平的影响结构(小鼠缺血1h,再灌注24h后,图A:采用Westernblotting技术检测小鼠脑组织中NAGK蛋白水平的表达情况(n=6);图B:采用q-PCR检测NAGK mRNA表达水平(n=6);结果以mean±SD表示,##P<0.01vs.Sham group,**P<0.01vs.Model group)。
具体实施方式
下面结合实施例对本发明的技术方案作进一步说明。
实施例1:N-乙酰葡萄糖胺激酶激动剂的遴选与初步验证
1、基于DrugBank药物数据库对NAGK的激动剂进行筛选
从DrugBank药物数据库中对NAGK相关的激动剂进行挖掘。重点初步预测激动NAGK作用的潜在上市药物约1800多种,排除已在脑卒中领域报道过及毒副作用较大的药物外,按得分高低顺序分类列出极具代表性的重要上市药物(前50种),但不限含有类似结构的药物,筛选结果如表1所示,遴选出得分最高的上市药物是西曲瑞克,提示其可能是NAGK的激动剂,拟通过体内外实验进行验证。
表1.利用DrugBank药物数据库预测出NAGK激动剂的相关上市药物
2、基于分子对接技术的结合自由能分析
从初步筛选得到的上市药物中选取得分最高的代表即西曲瑞克与靶蛋白NAGK进行分子对接,计算分子间结合自由能及具体结合部位,AutoDock 4.1软件将西曲瑞克与NAGK进行对接,PyMol软件进行可视化分析。其中NAGK与西曲瑞克的对接结果如图1所示,结合自由能为-10.3kcal/mol,可见得分最高的上市药物西曲瑞克与NAGK的结合能<-5kcal/mol,说明从DrugBank数据库筛选得到的激动剂西曲瑞克能够与NAGK较稳定地结合。
3、体外检测N-乙酰葡萄糖胺激酶激动剂西曲瑞克对酶活性的影响
图2在体外检测西曲瑞克对N-乙酰葡萄糖胺激酶活性的影响,结果显示,西曲瑞克对N-乙酰葡萄糖胺激酶的活性存在直接的激动作用,其中IC50为2.279μmol/L。进一步提示西曲瑞克可能是N-乙酰葡萄糖胺激酶的直接激动剂。
4、MST技术检测西曲瑞克与N-乙酰葡萄糖胺激酶的相互作用
首先使用MonolithTM RED-NHS二代蛋白标记试剂盒标记N-乙酰葡萄糖胺激酶重组蛋白,运用MST技术考察西曲瑞克与N-乙酰葡萄糖胺激酶的结合能力。结果如图3所示,Kd值为413.61±84.87nM,表明西曲瑞克能与N-乙酰葡萄糖胺激酶相互作用,进一步证实西曲瑞克能与N-乙酰葡萄糖胺激酶相结合。
实施例2:西曲瑞克对脑缺血再灌注诱导的模型小鼠脑损伤的改善作用
1、实验方法
(1)小鼠大脑中动脉阻塞及复灌的动物模型制备
参照依据文献建立的小鼠大脑中动脉阻塞及复灌(Middle cerebral arteryocclusion/reperfusion,MCAO/R)模型,采用线栓法制备,选择C57雄性小鼠,体重在20-22g之间。小鼠腹腔注射3%戊巴比妥钠,麻醉后,仰卧位固定,颈部中线切口。分离并暴露右侧的颈总动脉、颈外动脉及颈内动脉,依次在颈总动脉近心端预留结扎线,远心端结扎颈外动脉,并游离颈外动脉远端。沿颈内动脉向深部游离一段颈内动脉,于颈外动脉近心端预留结扎线。采用小型无创血管夹夹闭近心端颈总动脉及远端颈内动脉,于颈外动脉远心端用显微剪刀剪一小口,插入线栓通过颈总动脉分叉,进入颈内动脉。插入线段直至遇到轻微阻力,此时线段头端插入大脑前动脉约1mm。插线结束后,将预先放置于颈外动脉的结扎线缚紧。MCAO 60min后,分离暴露颈外动脉,松开固定线,拔除线栓,松开颈总和动脉结扎线实现再灌注,常规缝合颈部伤口。手术过程中动物肛温保持在37℃,术后将动物置于放有清洁垫料的饲养盒中自由饮水、进食。
建立MCAO/R模型后,动物分为假手术组(Sham组)、模型组、模型给药组(MCAO/R+西曲瑞克10mg/kg)、阳性对照组(尤瑞克林0.0025PNA/kg),除假手术组不插入线栓外,其余处理同其他组。再灌注同时腹腔注射给药,假手术组和模型组腹腔注射生理盐水。24h后进行行为学评价,取脑收集样本。
(2)西曲瑞克溶液的制备和给药方法
将醋酸西曲瑞克制备为治疗缺血性脑卒中的药物的方法:首先将醋酸西曲瑞克粉末溶解于生理盐水中制备得20mg/kg的醋酸西曲瑞克溶液,然后再加入生理盐水稀释得到10mg/kg的给药剂量。
(3)TTC染色测定脑梗死体积
小鼠脑缺血再灌注24h后,处死取脑,放入-20℃冰箱至脑组织完全冻住,然后在冰盒上将冻好的脑组织切成5片厚约2mm的冠状脑切片,迅速将切好的脑片放入1%2,3,5-三苯基四唑氯铵(2,3,5-Triphenyltetrazolium chloride,TTC)溶液中,注意朝一个方向放置脑片。随后,在37℃孵箱中避光孵育30min。置于黑色纸板上拍照传入电脑,采用Image J图像分析软件测量脑梗死体积。计算公式如下:
梗死体积百分比=右半脑梗死体积/脑总体积×100%
(4)神经行为学评分
神经功能障碍是缺血性脑卒中损伤评价的重要指标之一。小鼠缺血再灌注24h后,按照Longa神经功能评分考察神经功能障碍行为学,将神经功能损伤分为5个等级:0分:正常,无神经功能缺损;1分:右侧(瘫痪侧)前爪不能完全伸展,但行走时无明显转圈,轻微神经功能缺损;2分:小鼠向右测转圈,行走缓慢,中度神经功能缺损;3分:小鼠身体向右侧倾倒,缓慢转小圈,重度神经功能缺损;4分:不能自发行走,意识丧失。
(5)苏木精-伊红染色法
再灌注24h后将各组小鼠处死,取脑,用4%多聚甲醛固定24h以上,进行石蜡包埋、切片,H&E染色,随后用数字病理切片扫描仪扫描观察并拍照,考察脑组织的病理损伤情况。
2、实验结果
(1)西曲瑞克减少MCAO/R模型小鼠脑梗死体积
如图4(A)所示,Sham组小鼠脑组织呈红色,未见明显梗死区域。MCAO/R组小鼠缺血侧有严重的白色梗死灶,MCAO/R+西曲瑞克(10mg/kg)组与尤瑞克林(HUK)给药组小鼠右脑的梗死区域显著减小。图4(B)为各组脑梗死体积半定量图。经统计,与Sham组相比,MCAO/R模型组小鼠的脑梗死体积显著增加。而与MCAO/R模型组相比,MCAO/R+西曲瑞克(10mg/kg)组与尤瑞克林(HUK)给药组小鼠的脑梗死体积在给药后显著减少。
(2)西曲瑞克改善MCAO/R模型小鼠脑组织病理损伤以及神经功能损伤
如图5(A)所示,相较于Sham组,MCAO/R组小鼠脑组织出现空泡化、细胞核发生固缩、神经细胞数量减少,血管周围腔隙增宽。而给药后,西曲瑞克治疗组(10mg/kg)小鼠脑组织相较于MCAO/R组损伤明显减轻。如图5(B)所示,Sham组小鼠未出现明显神经功能损伤,与Sham组相比,MCAO/R组小鼠神经功能学评分明显升高。与MCAO/R组相比,缺血后给予西曲瑞克(10mg/kg),能够明显减少模型小鼠神经功能损伤。
实施例3:西曲瑞克改善脑缺血再灌注诱导的模型小鼠血脑屏障功能紊乱
1、实验方法
(1)伊文思蓝检测小鼠血脑屏障通透性
利用尾静脉注射伊文思蓝的方法,考察微血管的渗出性。MCAO/R造模22h后,各组小鼠尾静脉注射2%伊文思蓝溶液,循环2h后,小鼠心脏灌注1×PBS至血液冲净,取出完整大脑,拍照。取大脑右半球(缺血侧大脑),于生理盐水中洗去残留血丝,用滤纸适当吸干并称重,预冷的甲酰胺和脑组织按1mL:0.1g的比例进行匀浆,移至1.5mL EP中,离心机预冷到4℃,转速13000r/min,离心20min,取上清液,在620nm波长处测定吸光度,最后根据标准曲线计算含量。
(2)Western blotting技术检测小鼠脑组织中紧密连接蛋白和金属基质蛋白酶的表达量
各组小鼠于脑缺血再灌注手术后24h处死,1×PBS缓冲溶液进行心脏灌注,取脑,于生理盐水中洗去残留血丝,取缺血半暗带脑组织进行蛋白质免疫印迹,分析各组ZO-1、Occludin、MMP-9、MMP-2表达量。
组织蛋白提取方法:各组小鼠MCAO/R 24h后,断头处死,取缺血侧皮层固体组织0.1g提取蛋白,加入组织裂解液匀浆,于4℃条件下裂解30min。在4℃离心机中13000rpm离心10min,取上清液,测定蛋白含量。剩余的上清液加入5ⅹloading buffer,蛋白变性后,分别上样于10%SDS-PAGE凝胶中进行分析。湿法转膜后的条带孵育对应的一抗过夜,然后孵育对应的二抗,最后利用ECL试剂盒显影,采用凝胶成像仪进行条带曝光,目标蛋白表达量表示为相应内参蛋白表达量的相对值。
2、实验结果
(1)西曲瑞克减少脑缺血再灌注诱导的小鼠脑组织中伊文思蓝的渗漏量
图6(A-B)所示,与Sham组相比,MCAO/R组小鼠脑组织伊文思蓝渗漏明显。与MCAO/R组相比,MCAO/R+西曲瑞克(10mg/kg)组和HUK组明显降低MCAO/R后小鼠脑组织伊文思蓝的渗漏。结果表明,西曲瑞克能减少脑缺血再灌注诱导的小鼠脑组织中血脑屏障的损伤。
(2)西曲瑞克增加MCAO/R模型小鼠脑组织中紧密连接蛋白的表达
紧密连接蛋白ZO-1和Occludin的降解是脑缺血后血脑屏障损伤的重要病理环节,同时也是血脑屏障结构重要的组成部分。如图7(A-B)所示,相较Sham组,MCAO/R组ZO-1和Occludin的表达明显降低。而给药后,西曲瑞克治疗组(10mg/kg)使ZO-1和Occludin的表达显著增加。结果表明,西曲瑞克对MCAO/R模型小鼠的血脑屏障功能紊乱具有改善作用。
(3)西曲瑞克降低MCAO/R模型小鼠脑组织中金属基质蛋白酶的表达
MMP-2/9是脑缺血再灌注发生后促进紧密连接蛋白以及细胞基底膜降解的关键分子,同时也是参与炎症反应的重要因子。如图8(A-B)所示,相较于Sham组,MCAO/R组脑组织中MMP-2和MMP-9的表达水平明显升高。而给药后,西曲瑞克治疗组(10mg/kg)能够显著降低脑组织中MMP-2/9的表达水平。结果表明,西曲瑞克对MCAO/R模型小鼠的血脑屏障功能紊乱具有改善作用。
实施例4:激动剂西曲瑞克对MCAO/R诱导小鼠脑组织中NAGK表达的影响
1、实验方法
(1)Westernblotting技术检测小鼠脑组织中NAGK的表达量
建立MCAO/R模型后,动物分为假手术组(Sham组)、模型组、假手术+给药组(Sham+西曲瑞克10mg/kg)、模型+给药组(MCAO/R+西曲瑞克10mg/kg),除假手术组和假手术+给药组不插入线栓外,其余处理同其他组。各组小鼠于脑缺血再灌注手术后24h处死,1×PBS缓冲溶液进行心脏灌注,取脑,于生理盐水中洗去残留血丝,取缺血半暗带脑组织进行蛋白质免疫印迹,分析各组小鼠脑组织中NAGK的表达水平。
组织蛋白提取方法:各组小鼠MCAO/R24 h后,断头处死,取缺血侧皮层固体组织0.1g提取蛋白,加入组织裂解液匀浆,于4℃条件下裂解30min。在4℃离心机中13000rpm离心10min,取上清液,测定蛋白含量。剩余的上清液加入5ⅹloadingbuffer,蛋白变性后,分别上样于10%SDS-PAGE凝胶中进行分析。湿法转膜后的条带孵育对应的一抗过夜,然后孵育对应的二抗,最后利用ECL试剂盒显影,采用凝胶成像仪进行条带曝光,目标蛋白表达量表示为相应内参蛋白表达量的相对值。
(2)q-PCR技术检测小鼠脑组织中NAGK基因的表达量
①RNA提取与纯化
将各组脑组织放入液氮,称取0.1g右侧大脑组织,在2mL无酶管中加入1mLTrizol,采用研磨机进行研磨,加入氯仿200μL,剧烈震荡15s成乳浊液,静置5min,然后离心(4℃,12000rpm,15min)。转移上层水相(约450μL)到1.5ml的离心管中,加入等体积预冷的异丙醇,静置10min,离心(4℃,12000rpm,10min)。弃上清液,加预冷的75%乙醇1ml,涡旋,离心(4℃,12000rpm,5min)。弃上清并将残余乙醇挥发,加入20μL的DEPC水溶解RNA沉淀,以上步骤均在冰盒上操作,使用Nano-100微量核酸检测仪测定RNA浓度。
②逆转录反应以及qRT-PCR
根据说明书操作采用1st Strand cDNA Synthesis Kit进行逆转录,最后采用ChamQTM/>qPCR MasterMix进行实时荧光定量PCR。PCR的扩增参数为:95℃下5min,激活DNA聚合酶,变性,95℃(10s);退火,60℃(30s),共进行39次循环。反应结束后,查看引物和目的基因的扩增曲线以及融解曲线(65℃、0.05s,95℃、0.5s)。通过计算/>值来表示目的基因NAGK mRNA表达进行相对定量。基因表达归一化为β-actin,在单独的试管中进行评估,以便定量靶基因。其中Ct值为循环次数的平均值,ΔCt为目的基因Ct值减去内参基因β-actin Ct值。本实验中使用的引物如下:NAGK前引:CACGGTCCAAAGTCCTTTTACT后引:GTCTGTGCCAATCAGCCAGT;β-actin前引:GGCTGTATTCCCCTCCATCG后引:CCAGTTGGTAACAATGCCATGT。
2、实验结果
采用Western blotting技术考察西曲瑞克对小鼠脑缺血再灌注后脑组织中NAGK表达的影响,如图9(A)所示,MCAO/R组相较于Sham组,脑组织中NAGK表达显著降低,经统计,与Sham组相比,具有显著性差异(P<0.01)。缺血后给予西曲瑞克(10mg/kg)可促进脑组织中NAGK的表达,经统计,与MCAO/R组相比,具有显著性差异(P<0.01)。与Sham组相比,Sham+CTX组对NAGK的表达没有显著性差异。采用q-PCR检测MCAO/R小鼠脑组织中NAGK mRNA的表达,如图9(B)所示,MCAO/R组相较于Sham组,脑组织中NAGK mRNA表达显著降低,经统计,与Sham组相比,具有显著性差异(P<0.01)。缺血后给予西曲瑞克(10mg/kg)可促进脑组织中NAGK mRNA的表达,经统计,与MCAO/R组相比,具有显著性差异(P<0.01)。与Sham组相比,Sham+CTX组对NAGK mRNA的表达没有显著性差异。上述结果说明,西曲瑞克能够显著地增加MCAO/R模型小鼠脑组织中NAGK的表达水平。
Claims (10)
1.西曲瑞克在制备预防或/和治疗脑血管疾病、神经退行性疾病的药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述药物预防或/和治疗脑卒中的药物。
3.根据权利要求2所述的应用,其特征在于,所述药物为预防或/和治疗缺血性脑卒中的药物。
4.根据权利要求3所述的应用,其特征在于,所述药物为预防或/和治疗脑缺血再灌注损伤的药物。
5.根据权利要求1所述的应用,其特征在于,所述药物为N-乙酰葡萄糖胺激酶激动剂药物。
6.根据权利要求5所述的应用,其特征在于,所述药物能够提高N-乙酰葡萄糖胺激酶活性或/和表达水平,改善血脑屏障功能紊乱。
7.根据权利要求4所述的应用,其特征在于,所述药物能够减少脑梗死体积,缓解神经功能障碍,改善脑组织损伤。
8.根据权利要求4所述的应用,其特征在于,所述药物能够上调脑组织中紧密连接蛋白的表达水平。
9.根据权利要求4所述的应用,其特征在于,所述药物能够下调金属基质蛋白酶的表达水平。
10.一种以西曲瑞克作为活性成分的药物组合在制备预防或/和治疗脑缺血再灌注损伤的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311579285.4A CN117771344A (zh) | 2023-11-24 | 2023-11-24 | 西曲瑞克的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311579285.4A CN117771344A (zh) | 2023-11-24 | 2023-11-24 | 西曲瑞克的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117771344A true CN117771344A (zh) | 2024-03-29 |
Family
ID=90397206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311579285.4A Pending CN117771344A (zh) | 2023-11-24 | 2023-11-24 | 西曲瑞克的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117771344A (zh) |
-
2023
- 2023-11-24 CN CN202311579285.4A patent/CN117771344A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10335455B2 (en) | Method for prevention or treatment of intractable inflammatory bowel disease | |
ES2311973T3 (es) | Ctgf como objetivo para la terapia de microalbuminuria en pacientes con nefropatia diabetica. | |
KR20160124914A (ko) | 치료적으로 활성인 화합물의 약제학적 조성물 | |
KR20180100663A (ko) | 대사 기능장애에 의하여 유도된 종양에 대한 치료 | |
JP2018048178A (ja) | オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 | |
US20210024594A1 (en) | Therapeutic Agent for Psoriasis | |
US11819481B2 (en) | Supramolecular hydrogel applications to the carotid bodies to treat hypertension and sleep apnea in obesity | |
US20230108970A1 (en) | Methods and compositions for improving kidney function in patients with hepatorenal syndrome | |
US20050239759A1 (en) | Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor | |
PT1768691E (pt) | Composições contendo aequorina e métodos para sua utilização | |
US9296692B2 (en) | Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury | |
WO2009015561A1 (fr) | Utilisation de léonurine et compositions | |
JPH11508894A (ja) | Ace阻害剤とaii拮抗薬を用いる腎疾患の治療方法 | |
WO2019006692A1 (zh) | 用于治疗、改善或预防神经系统相关病症的化合物及其用途 | |
CN117771344A (zh) | 西曲瑞克的应用 | |
US20220362215A1 (en) | Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound | |
JP2009501795A (ja) | 高尿酸血に関連する健康状態の治療及び予防のための組成物及び方法 | |
JP5791064B2 (ja) | 医薬用組成物 | |
WO2019006690A1 (zh) | 多肽的药学可接受的盐及其应用 | |
WO2017185249A1 (zh) | 兴奋性神经毒性相关损伤的治疗肽 | |
WO2021115412A1 (zh) | 一氧化氮合酶通路抑制剂在制备药物中的用途 | |
JP7255056B2 (ja) | 脳卒中の予防または治療における安定性の高いマンガン型スーパーオキシドディスムターゼの使用 | |
US10647745B2 (en) | Compound for treating sequelae of ischemic cerebral stroke | |
WO2023245470A1 (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 | |
CN117257803A (zh) | 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |